Sanofi-Aventis Suspends Phase III Acomplia Trial in Japan
This article was originally published in PharmAsia News
Executive Summary
Sanofi Aventis announced Nov. 6 that the company decided to halt all clinical trials for obesity drug Acomplia (rimonabant) in compliance with European Medicines Agency's recommendation. The company has three ongoing Phase III trials in Europe and one in Japan for rimonabant. The company suspended marketing the drug in 18 European countries Oct. 23 due to the EMEA's recommendation. The agency cited mental disorder risks. Rimonabant is currently sold in 14 countries outside Europe. (Click here for more - Japanese language
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.